NCT00664859View on ClinicalTrials.gov

12-Month, Open-Label, Extension Study of LCP-AtorFen in Dyslipidemia

PHASE2/PHASE3CompletedINTERVENTIONAL

Enrollment

140

Participants

Timeline

Start Date

October 31, 2007

Primary Completion Date

February 28, 2009

Study Completion Date

February 28, 2009

Conditions

Dyslipidemia

Interventions

DRUG

LCP-AtorFen

All subjects will be assigned to receive open-label LCP-AtorFen combination therapy for 52 weeks. Subjects will take a single oral dose of study drug in the evening without regard to meals.

Trial Locations (1)

60610

Radiant Research, 515 N State St, Suite 2700, Chicago